Market Overview - The Hang Seng Index (HSI) closed at 25,129.61, down by 47.24 points or 0.19% as of August 18, 16:00 Eastern Time [1] - The index experienced a trading range with a high of 25,246.78 and a low of 25,127.88, indicating a volatility of 0.47% [1] Major Blue-Chip Stocks Performance - Most large-cap stocks declined, with HSBC Holdings closing at HKD 98.450, down by HKD 1.850 or 1.84% [2] - Tencent Holdings closed at HKD 587.000, down by HKD 5.000 or 0.84%, while its ADR price was HKD 586.613, reflecting a slight decrease of 0.387 [2] - Alibaba Group (ADR) saw a slight increase, closing at HKD 118.600, up by HKD 0.500 or 0.42%, with its ADR price at HKD 118.660, up by 0.060 [2] Notable Stock Movements - Meituan-W experienced a minor decline, closing at HKD 121.500, down by HKD 0.200 or 0.16%, while its ADR price was HKD 122.218, up by 0.718 [2] - Pop Mart International's stock surged, closing at HKD 284.800, up by HKD 13.400 or 4.94%, with its ADR price at HKD 284.470, down by 0.330 [2] - JD Group saw an increase, closing at HKD 124.000, up by HKD 3.200 or 2.65%, with its ADR price at HKD 124.211, up by 0.211 [2]

Core Insights - BeiGene, Ltd. (百济神州) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2] Financial Performance - As of June 30, 2025, BeiGene reported total revenue of $2.433 billion, representing a year-over-year growth of 44.73% [1] - The company's net profit attributable to shareholders was $95.59 million, showing a significant increase of 125.73% year-over-year [1] Product Portfolio - BeiGene has a comprehensive product portfolio that includes six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2] - The company has also obtained licenses for five drugs and investigational drugs, including three drugs (ABRAXANE, REVLIMID, and VIDAZA) exclusively licensed from Celgene that are already marketed in China, along with two investigational drugs in clinical stages [2] Company Background - Founded in Beijing in 2010, BeiGene was listed on the NASDAQ Global Select Market in February 2016 [2] - As of July 2018, the company had a global team of over 1,300 employees, showcasing its comprehensive capabilities in research, clinical development, manufacturing, and commercialization [2]

Group 1 - The Hong Kong stock market experienced a rise and then a pullback, with the Hang Seng Index reaching a new high [1] - The National Healthcare Security Administration is publishing a list of drugs that have passed preliminary review for the "2025 National Medical Insurance Directory and Commercial Insurance Innovative Drug Directory," which will enter expert review and negotiation stages [1][2] - The Hong Kong Innovative Drug Selected ETF (520690) saw a nearly 2.5% increase, with a trading volume exceeding 20 million and a turnover rate over 5%, indicating strong market interest [1] Group 2 - The dual-track policy of basic medical insurance and commercial insurance for innovative drugs signals a payment closure model, suggesting that "true innovation is easier to scale" [2] - The performance of innovative drugs is expected to be positively impacted by the dual-track payment system and significant business development opportunities, leading to a systematic revaluation of the Chinese innovative drug sector [2] - The Hang Seng Medical ETF (513060) is benefiting from the dual advantages of technology penetration and market expansion, particularly in AI healthcare and innovative drug companies [3]

Group 1 - Public funds have conducted over 3,800 research visits in the past month, with more than 150 institutions participating, indicating a strong interest in stock selection [2][3] - The average stock price increase of the companies researched by public funds reached 14.96%, significantly outperforming the market, with the top ten stocks seeing increases exceeding 73% [2] - The most favored sectors by public funds are TMT (Technology, Media, and Telecommunications) and pharmaceuticals, with 63 electronic companies and 47 pharmaceutical companies being researched extensively [3] Group 2 - The focus on AI technology is seen as a revolutionary change, with ongoing demand expected to drive growth across various industries [3] - In the pharmaceutical sector, there is an expectation of increased revenue for innovative drug companies, attracting long-term investments, with 2025 projected as a pivotal year for profitability [4] - The Chinese pharmaceutical industry is undergoing a valuation reset, with expectations of extended product life cycles and increased sales peaks due to the integration of commercial strategies [4]

Market Overview - The Hang Seng Index (HSI) closed at 25,237.96, down by 32.11 points or 0.13% on August 15 [1] - The index reached a high of 25,311.59 and a low of 25,199.63 during the trading session [1] Major Blue-Chip Stocks Performance - HSBC Holdings closed at HKD 99.966, down 0.33% from the previous close [2] - Tencent Holdings closed at HKD 591.706, down 0.05% from the previous close [2] Stock Price Movements - Tencent Holdings (00700) increased by HKD 2.00, or 0.34%, to HKD 592.00 [3] - Alibaba Group (09988) decreased by HKD 3.70, or 3.04%, to HKD 118.10 [3] - China Construction Bank (00939) fell by HKD 0.18, or 2.26%, to HKD 7.80 [3] - HSBC Holdings (00005) decreased by HKD 0.10, or 0.10%, to HKD 100.30 [3] - Xiaomi Group (01810) dropped by HKD 0.35, or 0.66%, to HKD 52.85 [3] - AIA Group (01299) fell by HKD 1.95, or 2.54%, to HKD 74.95 [3] - Meituan (03690) decreased by HKD 2.70, or 2.17%, to HKD 121.70 [3] - NetEase (099999) dropped by HKD 7.60, or 3.66%, to HKD 200.20 [3] - Hong Kong Exchanges and Clearing (00388) increased by HKD 0.20, or 0.05%, to HKD 439.40 [3] - Industrial and Commercial Bank of China (01398) fell by HKD 0.19, or 3.09%, to HKD 5.96 [3] - Ping An Insurance (02318) decreased by HKD 0.30, or 0.52%, to HKD 57.60 [3] - BYD Company (01211) dropped by HKD 1.00, or 0.88%, to HKD 112.80 [3] - Bank of China (03988) fell by HKD 0.09, or 1.98%, to HKD 4.45 [3] - Kuaishou Technology (01024) decreased by HKD 0.40, or 0.53%, to HKD 74.80 [3] - Ctrip (09961) increased by HKD 1.80, or 0.37%, to HKD 489.00 [3] - Tencent Music (01698) decreased by HKD 0.90, or 0.89%, to HKD 99.90 [3] - BeiGene (06160) increased by HKD 6.50, or 3.51%, to HKD 191.50 [3]

Core Insights - BeiGene, Ltd. (百济神州) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecular targeted and immunotherapy drugs for cancer treatment [2] - The company's stock opened at $316.0 per share, with a market capitalization of $37.43 billion as of August 15 [1] Financial Performance - As of June 30, 2025, BeiGene reported total revenue of $2.433 billion, representing a year-over-year growth of 44.73% [1] - The net profit attributable to the parent company reached $95.59 million, showing a significant increase of 125.73% compared to the previous year [1] Product Portfolio - BeiGene has a comprehensive product portfolio that includes six internally developed clinical candidates, three of which are in late-stage clinical trials: zanubrutinib (BTK inhibitor), tislelizumab (PD-1 antibody), and pamiparib (PARP inhibitor) [2] - The company has also obtained licensing rights for five drugs and investigational products, including three drugs (ABRAXANE, REVLIMID, and VIDAZA) exclusively licensed from Celgene, which are already marketed in China [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 審計委員會行動通告 百濟神州有限公司（「本公司」）謹此公佈，本公司董事會（「董事會」）審計委員會 將於2025年8月28日審議及批准（其中包括）本公司及其附屬公司截至2025年6月 30日止六個月的中期業績及根據香港聯合交易所有限公司證券上市規則（「香港上 市規則」）刊發中期業績。本公司先前於2025年8月6日公佈其截至2025年6月30日 止三個月及六個月的中期業績，並以提交表格10-Q的方式將其季度業績送交美國 證券交易委員會（「美國證券交易委員會」）存案。本公司根據香港上市規則將刊發 的中期業績與本公司先前已公佈並送交美國證券交易委員會存案者相同，惟根據 香港上市規則所要求的指定附加資料及將本公司的中期業績從美國公認會計原則 與國際財務報表準則進行核對的結果除外。 承董事會命 百濟神 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年8月15日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事 王曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon (Corsee) D. Sanders博士、Shalini Sharp女士及 易清清先生。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 審計委員會行動通告 百濟神州有限公司（「本公司」）謹此公佈，本公司董事會（「董事會」）審計委員會 將於2025年8月28日審議及批准（其中包括）本公司及其附屬公司截至2025年6 ...

Core Viewpoint - The company has demonstrated strong commercial performance and growth in its product portfolio, particularly with its leading BTK inhibitor, Baiyueze, which has achieved significant market share and revenue growth in various regions [3][6][9]. Group 1: Financial Performance - In Q2 2025, the company reported total revenue of $1.3 billion, a year-over-year increase of 42% [3][6]. - Baiyueze's global revenue reached $950 million, reflecting a 49% increase year-over-year, solidifying its position as the leading BTK inhibitor in the U.S. market [6][9]. - The gross margin improved from approximately 85% to 87.4%, driven by a favorable product mix and production cost efficiencies [6][9]. Group 2: Product Development and Pipeline - The company has submitted the first NDA for Sotokura for the treatment of relapsed/refractory CLL patients and plans to submit a global application for MCL indications later this year [4][5]. - The company is advancing over 20 Phase 3 trials and expects to achieve more than 10 concept validation data readouts by the end of 2026 [3][4]. - The company is focusing on expanding its product pipeline in various disease areas, including breast cancer and solid tumors, with a strategic emphasis on rapid clinical concept validation [5][12]. Group 3: Market Expansion and Regulatory Approvals - Baiyueze has been approved in 75 markets globally, with recent expansions in reimbursement coverage in five new markets [8][9]. - Baiyuean has been approved in 47 markets, with 20 new markets added for reimbursement, including Japan, Europe, and Australia [8][9]. - The company anticipates continued growth in revenue from diverse geographic markets, with the U.S. and China being the largest contributors [9][10]. Group 4: Future Guidance - The company updated its 2025 revenue guidance to a range of $5 billion to $5.3 billion, reflecting strong growth expectations for Baiyueze and ongoing market expansion [6][9]. - The company aims to achieve positive GAAP operating profit and expects to generate positive free cash flow for the year [6][9].

Group 1 - Hong Kong pharmaceutical and healthcare stocks experienced significant gains, with JD Health rising over 14%, Ping An Good Doctor increasing over 10%, and China National Pharmaceutical Group up over 4% [1] - Other notable stocks included Baijie Shenzhou, CSPC Pharmaceutical Group, and 3SBio, each rising over 3% [1] - The positive market sentiment also led to a rise in Hong Kong healthcare and Hong Kong Stock Connect pharmaceutical ETFs, which increased by over 2% [1] Group 2 - Analysis indicates that multinational pharmaceutical companies have significantly increased their procurement of innovative drug patents in China, with procurement amounts from January to May nearing the total expected for the entire year of 2024 [2] - This trend highlights the competitive strength of China's innovative drugs in the international market, suggesting that the acceleration of patent procurement by large multinational companies is likely to continue in the medium to long term [2]